PulseAugur
EN
LIVE 19:51:54
中文(ZH) “寻明生科”完成3500万美元A+轮融资

Xunming Bio secures $35M A+ round led by Sequoia China for AI platform

By PulseAugur Editorial · [1 sources] ·

Xunming Biotech, a company focused on AI-driven antibody design, has secured $35 million in Series A+ funding. The round was led by Sequoia China with participation from MatrixPartners China and Boyuan Capital, alongside existing investors. Funds will be allocated to advancing their AuraIDE™ platform, enhancing foundation models and agent capabilities, and expanding their experimental facilities to streamline the drug discovery and development process. AI

IMPACT Accelerates AI integration in drug discovery, potentially speeding up the development of novel therapeutics.

RANK_REASON Significant funding round for an AI-focused biotech company.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Xunming Bio secures $35M A+ round led by Sequoia China for AI platform

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Significant
Significant funding round for an AI-focused biotech company.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
funding, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
151 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Xunming Bio completes $35 million Series A+ funding round

    36氪获悉，“寻明生科”近期已完成3500万美元A+轮融资。本轮融资由红杉中国领投，经纬创投、博远资本跟投，老股东五源资本、启明创投、纽尔利资本等持续加注。寻明生科方面表示，本轮募集资金将用于推动自研创新功能抗体设计平台AuraIDE™建设，加大基座模型与智能体能力建设、完善高通量高内涵实验平台设施，进一步打通智能体从立项、分子设计到转化落地的关键环节。

RELATED ENTITIES

RELATED TOPICS